Thermo Fisher Scientific Human Endostatin Recombinant Protein, PeproTech

Applications

Tested Dilution

Publications

Western Blot (WB)

Assay-dependent

-

ELISA (ELISA)

Assay-dependent

-

Functional Assay (Functional)

Assay-dependent

-

In vitro Assay (IV)

-

View 1 publication 1 publication

Product Specifications

Species

Human

Published species

Human

Expression System

E. coli

Amino acid sequence

MHSHRDFQPV LHLVALNSPL SGGMRGIRGA DFQCFQQARA VGLAGTFRAF LSSRLQDLYS IVRRADRAAV PIVNLKDELL FPSWEALFSG SEGPLKPGAR IFSFDGKDVL RHPTWPQKSV WHGSDPNGRR LTESYCETWR TEAPSATGQA SSLLGGRLLG QSAASCHHAY IVLCIENSFM TASK

Molecular weight

20.2 kDa

Class

Recombinant

Type

Protein

Purity

≥ 98% by SDS-PAGE gel and HPLC analyses.

Endotoxin concentration

<1 EU/µg

Activity

Measured by its ability to inhibit HUVEC migration.

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Lyophilized

Purification

purified

Contains

no preservative

Storage conditions

-20°C

Shipping conditions

Ambient

Product Specific Information

Recombinant Human Endostatin is a 20.2 kDa protein consisting of 184 amino acid residues.

This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis

Target Information

Endostatin is able to avoke non-uniform response for proliferation, cell mount and migration of entothelial cells, which different endostatin binding characteristic, leads to the assumption that endostatin effect is strongly dependent from endothelial cell type. Furthermore endostatin inhibits angiogenesis and tumor growth in vivo by inducing apoptosis in endothelial cells. The local delivery of endostatin seems to specifically affect tumor-associated microvessels by reduction of the vessel density, diameter and functionality. Tumor cell migration and invasion was greatly reduced in the endostatin treated animals. Endostatin is non-toxic and does not induce aquired drug resistance and has therefor become a potent new therapy strategy in solid neoplasias. This therapy appears to have a high potential not only for the treatment of gliomas, the most common brain tumors, but also in other tumors. The ability of endostatin to inhibit neoangiogenesis is mediated, at least in part, by Zn^+2 binding and elastase processing. Widespread endostatin expression was found in elactic fibers in vessel walls and in some other basement membrane zones. Endostatin is released by neurons to accumulate in amyloid plaques in Alzheimer`s disease.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.